



Atty Dkt PP01617.002  
2300-1617  
PATENT

1648

#10  
Let. re: formal  
drawings  
**RECEIVED**  
4/24/01  
APR 19 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on April 11 2001

4/11/01  
Date

Gail Wardwell  
Signature

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

COIT et al.

Serial No.: 09/721,479

Group Art Unit: 1648

Filing Date: November 22, 2000

Examiner: Stacy Brown

Title: NOVEL HCV NON-STRUCTURAL POLYPEPTIDE

**SUBMISSION OF FORMAL DRAWINGS**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Attention: Official Draftsman

Sir:

Enclosed are 119 sheets of formal drawings in connection with the above identified case.

Respectfully submitted,

Date: April 11, 2001

By: D. Pasternak  
Dahna S. Pasternak  
Registration No. 41,411  
Attorney for Applicants

CHIRON CORPORATION  
Intellectual Property - R440  
P.O. Box 8097  
Emeryville, CA 94662-8097  
Telephone: 650-325-7812  
Facsimile: 650-325-7823



Atty Dkt No. PP01617.002  
PATENT

RECEIVED  
APR 19 2001  
TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on April 11, 2001.

4/11/01  
Date

Gail Wardwell  
Signature

#10  
Statement re:  
Seq. List  
4/20/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

COIT et al.

Serial No.: 09/721,479

Group Art Unit: 1648

Filing Date: November 22, 2000

Examiner: Stacy Brown

Title: NOVEL HCV NON-STRUCTURAL POLYPEPTIDE

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE  
WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:


The undersigned hereby states that the content of the attached papers and the computer-readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Date: April 11, 2001

By: Dahna S. Pasternak  
Dahna S. Pasternak  
Registration No. 41,411  
Attorney for Applicants

CHIRON CORPORATION  
Intellectual Property - R440  
P.O. Box 8097  
Emeryville, CA 94662-8097  
Telephone: (510) 923-2708  
Facsimile: (510) 655-3542



Dkt PP01617.002  
2302-1617  
PATENT

1648  
Bot seg

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on April 11 2001

4/11/01  
Date

Gail Wadswell  
Signature

#9  
Amend. a  
w/ Seg. Compl.  
4/20/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

COIT et al.

Serial No.: 09/721,479

Group Art Unit: 1648

Filing Date: November 22, 2000

Examiner: Stacy Brown

Title: NOVEL HCV NON-STRUCTURAL POLYPEPTIDE

RECEIVED

APR 19 2001

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed are the following in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed March 2, 2001 (see copy of Interview Summary Record restarting the response time) in the above-identified case:

- 1) copy of Interview Summary Record restarting the time for response to March 25, 2001;
- 2) Revised Sequence Listing in paper form (pp. 1-184) and on diskette;
- 3) Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§ 1.821-1.825; and
- 4) copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures

placed  
before.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-1648.

Respectfully submitted,

Date: April 11, 2001

By: Dahna S. Pasternak  
Dahna S. Pasternak  
Registration No. 41,411  
Attorney for Applicants

ROBINS & ASSOCIATES  
90 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: 650-325-7812

Facsimile: 650-325-7823



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/721,479 11/22/00 COIT

PP01617.002

EXAMINER
----------

BROWN, S


ART UNIT	PAPER NUMBER
----------	--------------

1649

DATE MAILED: 04/02/01

CHIRON CORPORATION  
INTELLECTUAL PROPERTY -R440  
P.O. BOX 8097  
EMERYVILLE CA 94662-8097

HM32/0402



COPY

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademark

2300 1617  
hook  
PATR  
DOCKETED  
Reverse Seq list  
4/25/01  
RECEIVED  
APR 19 2001  
TECH CENTER 1600/2900

DOCKETED on/by 4/6/01/ gaw  
Atty. AAH PA  
File # PP01617.002  
Due Date 4/27/01 Ext DLF  
Final Date DLF Interview Summary (if desired)

# Interview Summary



Application No.

09/721,479

Examiner

Stacy S Brown

Applicant(s)

COIT ET AL

Art Unit

1648

RECEIVED

APR 19 2001

TECH CENTER 1600/2900

COPY

All participants (applicant, applicant's representative, PTO personnel):

(1) Stacy S Brown.

(3) \_\_\_\_\_

(2) Gail Wardwell.

(4) \_\_\_\_\_

Date of Interview: 27 March 2001

Type: a) ☒ Telephonic b) ☐ Video Conference  
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.

If Yes, brief description: \_\_\_\_\_

Claim(s) discussed: \_\_\_\_\_

Identification of prior art discussed: \_\_\_\_\_

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: The examiner will reset the time for response to the notice to comply with sequence rules one month from the date of mailing the error report. The response date is now set for 25 April 2001

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

i) ☒ It is not necessary for applicant to provide a separate record of the substance of the interview(if box is checked).

Unless the paragraph above has been checked, THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

HANKYEL T. PARK, PH.D.  
PRIMARY EXAMINER

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Stacy S. Brown 4-2-01  
Examiner's signature, if required



Application No.: 09/721479

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**RECEIVED**

APR 19 2001

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**